Frontlight ResearchEarly access
Active, not recruitingPhase 1
Novel Transdermal Ketoprofen Gel Formulation for Knee Osteoarthritis
Key facts
- Who runs it
- New Valley University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 40 people enrolled
- Started
- 10 May 2025
- Ended
- Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ketoprofen
- Record updated
- 6 January 2026
Who can take part
- Age
- 45 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patient diagnosed with osteoarthritis in knee by:; Full history taking Physical examination including (joint tenderness, swelling, crepitus and limitation of motion)
Who cannot take part
- 1. Patients with dual diagnosis 2. Patients have skin lesion or dermatologic disease in the treatment area
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A single blind randomized controlled clinical study
The 2 groups in the trial
- formulation armTreatment being tested
new formulation of ketoprofen
Treatment: ketoprofen
- commercial productExisting treatment, for comparison
positive control receiving commercial product
Treatment: ketoprofen
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Novel Transdermal Ketoprofen Gel Formulation for Knee Osteoarthritis: Comprehensive In-Vitro and Clinical Assessment
- Record updated
- 6 January 2026